Biotech | December 22, 2021
Piramal Pharma takes a minority stake in Yapan Bio
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The company plans to expand their capacity to meet the needs of pharma and biotech industries
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
Subscribe To Our Newsletter & Stay Updated
